GUILLAIN–BARRÉ SINDROMIDA IMMUNOLOGIK BIOMARKERLARNING ERTA DIAGNOSTIK VA PROGNOSTIK AHAMIYATI
Abstract
Guillain–Barré syndrome (GBS) periferik asab tizimining o‘tkir, tez progresiyalanuvchi, immun vositachiligidagi poliradikulonevropatiyasi bo‘lib, demiyelinizatsiya yoki aksonal degeneratsiya bilan kechadi (1,2). Kasallik ko‘pincha respirator yoki gastroenteral infeksiyalardan so‘ng rivojlanib, molekulyar mimikriya mexanizmi orqali gangliozid strukturalariga qarshi autoantitanachalar ishlab chiqilishi bilan xarakterlanadi (3,4). Natijada komplement tizimi faollashuvi, makrofag infiltratsiyasi va Shvann hujayralari shikastlanishi yuz beradi.
References
1.Yuki N., Hartung H.P. Guillain–Barré syndrome. N Engl J Med. 2012;366(24):2294–2304.
2.Willison H.J., Jacobs B.C., van Doorn P.A. Guillain–Barré syndrome. Lancet. 2016;388(10045):717–727.
3.Hughes R.A.C., Cornblath D.R. Guillain–Barré syndrome. Lancet. 2005;366(9497):1653–1666.
4.van den Berg B., et al. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–482.
5.McGrogan A., et al. The epidemiology of Guillain–Barré syndrome worldwide. Neuroepidemiology. 2009;32(2):150–163.
6.Kieseier B.C., et al. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4:31.
7.Wanschitz J., et al. Hsp70 upregulation in peripheral nerves of patients with inflammatory neuropathies. Acta Neuropathol. 2003;105(5):453–458.
8.Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10(8):435–446.